James Rodberg - 08 Jan 2023 Form 3 Insider Report for Sight Sciences, Inc. (SGHT)

Role
Interim Chief Financial Officer Exhibit list: Exhibit 24 - Power of Attorney
Signature
/s/ Jeremy Hayden, Attorney-in-Fact for James Rodberg
Issuer symbol
SGHT
Transactions as of
08 Jan 2023
Net transactions value
$0
Form type
3
Filing time
18 Jan 2023, 20:36:09 UTC
Next filing
21 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SGHT Common Stock 699 08 Jan 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SGHT Stock Options (Right to Buy) 08 Jan 2023 Common Stock 27,500 $10.96 Direct F1
holding SGHT Stock Options (Right to Buy) 08 Jan 2023 Common Stock 13,100 $17.52 Direct F2
holding SGHT Restricted Stock Units 08 Jan 2023 Common Stock 22,300 Direct F3, F4
holding SGHT Restricted Stock Units 08 Jan 2023 Common Stock 3,300 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options were granted on May 25, 2021 and became exercisable as to 25% of the underlying securities May 16, 2022, with the remainder vesting in 36 substantially equal installments on a monthly basis thereafter, subject to the Reporting Person's continued service to the Company through each such date.
F2 These options were granted on February 9, 2022 and vest in 48 substantially equal installments on a monthly basis commencing February 1, 2022, subject to the Reporting Person's continued service to the Company through each such date.
F3 Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan (the "2021 Plan"). The RSUs shall vest in four equal installments on an annual basis from December 1, 2023 through December 1, 2026 subject to the Reporting Person's continued service to the Company through each vesting date. The RSUs have no expiration date.
F4 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F5 Reflects a grant of 4,400 RSUs made to the Reporting Person under the 2021 Plan, 1,100 of which vested on January 1, 2023. The remaining 3,300 RSUs shall vest in three equal installments on an annual basis from January 1, 2024 through January 1, 2026 subject to the Reporting Person's continued service to the Company through each vesting date. The RSUs have no expiration date.

Remarks:

Interim Chief Financial Officer Exhibit list: Exhibit 24 - Power of Attorney